Harnessing Host Defense Responses To Fight Cancer

Manhattan BioSolutions is an emerging biotech company focused on the development of novel biologic therapies that target microbial recognition and host-defense pathways for the treatment of advanced, metastatic cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues

Scientific Platforms

Degrader Nucleases

Developing a new generation of human nuclease therapeutics with potent anti-cancer activities. The RNA degrador platform utilizes engineered derivative of naturally occurring enzyme involved in host defense to selectively degrade RNA in tumors

ADCs & Ab Fusions

Developing novel biologics – ADCs & mAb-fusions that target cell-surface receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms

In the News
Contact Us
For business development or general inquiries, please fill out a contact form. If you’re an accredited investor, please contact us at ir @ manhattanbiosolutions.com

Manhattan Bio, Inc. Headquarters
477 Madison Avenue, 6th Floor
New York, NY 10022

80 5th Avenue, 1002
New York, NY 10011